In a previous study we demonstrated that antiviral response against the coliphage MS-2 can be elicited by immunization with a synthetic antigen consisting of a conjugate (P2-A --L) of a synthetic fragment (P2) of the virus coat protein attached to a synthetic polymeric carrier. The antiviral response was induced when the antigen was administered in complete Freund's adjuvant or when it was administered in incomplete adjuvant, provided that a peptidoglycan was covalently attached to it. In the present study we demonstrate the adjuvant effect of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) in this system. Immunization with a mixture of MDP and P2-A --L brought about only slight enhancement in the titer of neutralizing antibodies, as compared to the immunization with P2-A --L in saline. The best results were achieved when the MDP was chemically conjugated to P2-A --L. This completely synthetic material, when administered in aqueous solution, yielded highly inactivating antiserum with a titer similar to that obtained with complete Freund's adjuvant in the absence of MDP. MDP-P2-A --L elicited also a humoral immune response to MDP, but with much lower titer than that induced by complete Freund's adjuvant containing PrA --L only. It was also observed that the capacity of MDP-P2-A --L to increase resistance against infection was more than a 100-fold greater than that of unconjugated MDP. In the last few years progress has been made, and new approaches have been employed, in the field of vaccine preparation. This included the introduction of the concept of genetic engineering for production of viral components (1), in parallel with the chemical synthesis of viral fragments (2), for the purpose of replacing vaccines now used. If found successful, these approaches might show several advantages. (i) The fragments should contain only the unique antigenic determinant(s) required for eliciting neutralizing antibodies, thus eliminating undesired side effects caused by the presence of contaminating components or irrelevant determinants. (ii) The carrier to be used in a synthetic material could be chosen according to the genetic background of the immunized individual, taking advantage of the recent knowledge about the often-occurring correlations between an efficient immune response and the type of histocompatibility antigens of the host (3, 4). (iii) In a synthetic antigen the problem of adjuvanticity and choice of the desirable adjuvant might be solved by introduction into the macromolecule of groups to enhance immunogenicity.A prerequisite for this approach is the feasibility of synthesis of antigens that contain immunoreactive region(s) of protein molecules, including viral proteins, that will induce immune response toward the intact protein. Indeed, during the last few years this has been demonstrated for several proteins. For example, antibodies provoked by a synthetic peptide comprising the "loop" region of the enzyme lysozyme attached to a synthetic carrier were reactive with native lysozyme (5). Similarly, anti...